Mochi Health

About Mochi Health

Mochi Health has quickly become one of the most talked-about GLP-1 providers in the telehealth space, and for good reason. Founded in 2022, the platform combines affordable compounded medications with a level of clinical rigor that many budget-focused competitors lack — including dietitian access, bariatric specialists, and LegitScript certification.

Mochi offers both compounded semaglutide ($99/month) and compounded tirzepatide ($199/month), plus brand-name options like Wegovy and Zepbound for patients who prefer FDA-approved formulations. The membership runs $79/month, making the all-in cost competitive without sacrificing clinical quality. They also provide a Certificate of Analysis (CoA) for their compounded medications — a transparency measure that most competitors skip.

With 15,600+ Trustpilot reviews at a 4.4 rating, Mochi’s patient satisfaction metrics are among the strongest in the industry. That volume and rating combination is rare — it suggests consistent delivery, not just a handful of cherry-picked positive reviews.

Clinically, Mochi earns near-perfect marks. Patients get access to bariatric-trained providers, ongoing support, and a dietitian — features that support long-term weight management beyond just the prescription. The platform is available in all 50 states and offers both oral and subcutaneous delivery formats.

The one notable blemish is a D+ BBB rating, which appears driven by complaint volume relative to the company’s rapid growth rather than a pattern of deceptive practices. Given their LegitScript certification, CoA transparency, and strong Trustpilot performance, the BBB rating looks like a lagging indicator rather than a red flag.

Mochi Health GLP-1 Medications

At a Glance